At AADIGEN and its sister company DIVINCELL, we are harnessing the natural delivery and targeting capabilities of peptides to develop an entirely novel class of RNA-based therapeutic agents for the treatment of cancer and genetic diseases
We are a BioPharmaceutical company, pioneering novel peptide-based nanotechnology for targeted delivery of RNA therapeutics.
Peptide-based nanoparticulate systems, enabling the protection, packaging and tissue or cell targeting of small and large oligonucleotides.
We are working to create novel RNA-based therapeutics for cancers driven by tumor suppressor loss of function or inactivation and oncogene activation as well as other genetic diseases with a wide range of severe pathologies and limited treatment options.
